Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel versus standard of care in relapsed/refractory follicular lymphoma
NCT05371093Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Sep 2022
- Primary completion
- Oct 2030
- Modality
- CAR-T Cells
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Axicabtagene Ciloleucel with Standard of Care Therapy (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Started Sep 2022; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05371093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371093.